BSG and colorectal carcinoma: Novel biomarkers for the non-invasive diagnosis and prognosis of CRC have been found in feces-derived EVs, including CD147 and A33, which offer a clinical sensitivity of 89% compared to the commonly used serum biomarker for CRC diagnosis, a carcinoembryonic antigen (CEA) [81].